LAMP2 and cardiomyopathy: This treatment can increase patient survival, enhance LAMP2 expression in the myocardium, reduce levels of cardiac troponin I and natriuretic peptides, and improve New York Heart Association class and Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) scores.[19] Notably, a single infusion of RP-A501 appeared to be generally safe.[19] This represents a significant advancement for patients with DD and provides a new strategy for the treatment of DD.